September 11, 2023 — Polarean Imaging plc (AIM: POLX), a commercial-stage medical device leader in advanced magnetic resonance imaging (“MRI”) of the lungs, announces that it has partnered with VIDA Diagnostics (“VIDA”), a clinical imaging intelligence company providing medical imaging software solutions which manage the complexities of digital biomarkers. The companies are partnering to further enable the Polarean xenon 129 MRI platform to accelerate clinical and research use.
VIDA has empowered more than 1,000 clinical and research sites globally with its imaging management platform, a cloud-native AI-enabled solution that drives standardisation and efficiencies in clinical trial imaging operations. The platform includes a unique orchestration engine used to integrate and optimise multimodality clinical algorithms and enable new high-quality imaging biomarkers to be more accessible to researchers, and clinical trials, as well as adopted into the clinical care workflows.
The collaboration between Polarean and VIDA is intended to support the integration of xenon 129 MRI workflow into the clinical continuum of care to establish a clinical trial network for pharma-sponsored drug and device development using standardised xenon 129 MR image acquisition and data-sharing methods, and to create automated image processing workflows and algorithms. These new products and services will be utilised to expand access to xenon 129 MRI as a lung imaging service and to investigate new indications and biomarkers in broader populations with unmet medical needs. Additionally, through this collaboration, each company will foster new research collaborations and amplify the opportunities it can bring to its lung imaging customers.
Christopher von Jako, Ph.D., CEO of Polarean, said:“Polarean continues to cultivate partnerships with entities that enhance our core capabilities. We are excited to form this partnership with VIDA, a world-renowned organisation in the field of lung imaging software platform solutions and biomarker development, to capitalise on their complementary expertise. Furthermore, this partnership perfectly aligns with our objective of extending the reach of XENOVIEW MRI, to provide tools to physicians that treat patients suffering from chronic lung disease.”
Susan Wood, Ph.D., CEO of VIDA, said: “VIDA and Polarean are natural partners. Both companies share a goal of empowering providers with advanced medical imaging solutions to enhance clinical decisions and accelerate bringing new therapies to patients. We are excited at the prospect of expanding our imaging platform portfolio through our collaboration with Polarean, thereby introducing pioneering MRI-based lung imaging biomarkers.”
Polarean recently launched the first and only inhaled MRI hyperpolarised contrast agent, XENOVIEWTM (xenon Xe 129, hyperpolarised), for novel visualisation of lung ventilation. Since the technology is based on MRI, it does not expose patients to any ionising radiation and its associated risks. The dose of XENOVIEW, created through the Polarean HPX hyperpolarisation system, is administered in a single 10-15 second breath-hold MRI procedure. XENOVIEW is indicated for use with MRI for evaluation of lung ventilation in adults and paediatric patients aged 12 years and older. XENOVIEW has not been evaluated for use with lung perfusion imaging.
For more information: www.polarean-ir.com
May 04, 2026 
